Streetbeat News

Price Targets

SWTX

SpringWorks Therapeutics (SWTX) is projected by Wall Street analysts to have a potential upside of 92.7% based on the mean of their price targets. Despite the historical ineffectiveness of this metric, the consensus among analysts in raising earnings estimates suggests a positive outlook for the stock.

Portfolio Pulse from

November 14, 2024 | 4:15 pm

MNR

Wall Street analysts have set an average price target for Mach Natural Resources LP (MNR), indicating a potential upside of 45.7%. This is supported by a positive trend in earnings estimate revisions, suggesting potential stock price growth.

Portfolio Pulse from

November 14, 2024 | 4:15 pm

NVDA

A Wall Street analyst has set a price target of $178 for Nvidia stock, raising questions about whether it is a good buy at this level.

Portfolio Pulse from

November 14, 2024 | 3:00 pm

PLTR

T

The article predicts that two growth stocks will surpass AT&T in value within a year. These stocks are expected to experience significant growth, making them attractive investment opportunities.

Portfolio Pulse from

November 14, 2024 | 12:15 pm

PLTR

Wall Street analysts are warning investors about Palantir's stock as its price has surpassed all analyst targets.

Portfolio Pulse from

November 14, 2024 | 11:15 am

DVAX

Dynavax Technologies Corporation has announced a significant stock buyback authorization, leading to a rise in its share price. The company's flagship product, Heplisav-B, is gaining market share in a growing market, and Dynavax is moving towards profitability. Analysts have set price targets above the current trading level, even after a recent rally.

Portfolio Pulse from

November 14, 2024 | 12:00 am

ASLE

AerSale's Q3 sales fell by 10.6%, but margins improved. The company is expanding MRO capacity, expected to boost EBITDA by $50 million annually. Despite AerAware commercialization challenges, AerSale focuses on MRO growth and disciplined asset acquisition. The price target is increased to $8.17, driven by $70 million in insurance claims, despite reduced EBITDA and free cash flow estimates for 2025 and 2026.

Portfolio Pulse from

November 13, 2024 | 6:30 pm

CAVA

Cava reported strong Q3 results, leading to a significant increase in its stock price. Jefferies raised its price target for Cava from $117 to $195 and gave it a 'Buy' rating.

Portfolio Pulse from

November 13, 2024 | 5:45 pm

BUD

TAP

Anheuser-Busch InBev SA/NV (BUD) and Molson Coors Beverage Company (TAP) are compared as investment options. BUD is seen as a mid-level play with higher growth expectations, while TAP is a value play with lower growth expectations. Both are reasonably valued relative to forward EPS growth but risk becoming value traps. Key support levels for BUD are at $54, and TAP has a potential upside to $80-$82 if current support holds.

Portfolio Pulse from

November 13, 2024 | 5:00 pm

MAT

Wall Street analysts have set a mean price target for Mattel (MAT) that suggests a potential 26.4% upside. Despite the historical unreliability of price targets, the consensus among analysts in raising earnings estimates indicates a positive outlook for the stock.

Portfolio Pulse from

November 13, 2024 | 4:15 pm